Drugmaker Tactic to Block Generics May Violate Law, FTC Says

Updated on
  • FTC files amicus brief in Mylan appeal over antibiotic Doryx
  • Some drugmakers tweak products to extend patent protection

Pharmaceutical companies that make minor tweaks to brand-name drugs in order to blunt competition from cheaper generic treatments may be violating antitrust laws, the U.S. Federal Trade Commission said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.